Jun 2026 (Q2 FY26) — Aug 10, 2026
Heron Therapeutics Q2 FY26 — Mixed Commercial Performance and Strategic Review
Read the full callHeron Therapeutics (HRTX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Heron Therapeutics earnings: last reported Mon, 10 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 37.7 | +1.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -5.4 | −1.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -5.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.36 0.00% · $0
Performance −72.1% 1Y
1Y: $1.29 on 17 Oct 2025 → $0.36. High $1.49 (12 Jan 2026), low $0.27 (21 Sept 2026).
- Previous close
- $0.36
- 52-week range
- $0.27 – $1.49
- One year
- −73.33%
Overview
- Symbol
- HRTX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Heron Therapeutics earnings calls (HRTX)
Financials
What the filings say
Net profit, year on year: −131% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 33 | 41 | 39 | 37 | 38 | 41 | 35 | 38 |
| Expenses | 28 | 26 | 27 | 29 | 30 | 29 | 29 | 28 |
| Operating profit | -4 | 4 | 3 | -2 | -4 | 0 | -5 | -2 |
| Operating margin | −13.6% | 10.2% | 8.1% | −4.4% | −10.7% | 0.1% | −13.7% | −5.4% |
| Net profit | -5 | 4 | 3 | -2 | -17 | -3 | -8 | -5 |
| EPS ($ per share) | -0.03 | — | 0.02 | -0.02 | -0.10 | — | -0.04 | -0.03 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Reserves | -961 | -1,165 | -1,393 | -1,613 | -1,795 | -1,906 | -1,920 | -1,940 |
| Total liabilities | 92 | 109 | 117 | 228 | 237 | 256 | 267 | 242 |
| Fixed assets | 15 | 20 | 23 | 24 | 22 | 20 | 15 | 12 |
| Total assets | 462 | 513 | 354 | 306 | 251 | 223 | 233 | 256 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -192 | -125 | -185 | -203 | -147 | -59 | -23 | -28 |
| Cash from investing | -279 | -22 | 209 | 33 | -3 | 18 | 19 | 16 |
| Cash from financing | 358 | 186 | 9 | 156 | 75 | 54 | 1 | 14 |
| Net cash flow | -113 | 40 | 33 | -15 | -75 | 13 | -3 | 3 |
| Capital expenditure | -9 | -7 | -7 | -3 | -2 | -2 | -2 | -0 |
| Free cash flow | -201 | -132 | -192 | -206 | -149 | -60 | -24 | -28 |
Insider filings
49 filings between Oct 31, 2025 and Aug 6, 2026.
Open market
decisions to buy or sellNobody bought or sold HRTX on the open market in this window. The filings below are 7 awards, 34 option exercises and 8 tax withholdings.
Compensation
not trading decisions- 7
- Award — granted as compensation
- 34
- Option exercise — converted options into shares
- 8
- Tax withheld — shares kept back by the company to cover tax
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 6, 2026 | Hensley Mark Earl Chief Operating Officer | Option exercise | 31,250 | — |
| Aug 6, 2026 | Hensley Mark Earl Chief Operating Officer | Tax withheld | 8,888 | $4.4K |
| Jul 31, 2026 | Forbes William P EVP, Chief Development Officer | Option exercise | 11,694 | — |
| Jul 31, 2026 | Collard Craig A Chief Executive Officer | Option exercise | 34,789 | — |
| Jul 31, 2026 | Duarte Ira EVP, Chief Financial Officer | Option exercise | 11,694 | — |
| Jul 31, 2026 | Duarte Ira EVP, Chief Financial Officer | Tax withheld | 3,326 | $1.7K |
| Jul 31, 2026 | Forbes William P EVP, Chief Development Officer | Tax withheld | 3,326 | $1.7K |
| Jul 31, 2026 | Hensley Mark Earl Chief Operating Officer | Option exercise | 11,769 | — |
| Jul 30, 2026 | Forbes William P EVP, Chief Development Officer | Tax withheld | 3,348 | $1.7K |
| Jul 30, 2026 | Forbes William P EVP, Chief Development Officer | Option exercise | 11,769 | — |
| Jul 30, 2026 | Collard Craig A Chief Executive Officer | Option exercise | 50,021 | — |
| Jul 30, 2026 | Duarte Ira EVP, Chief Financial Officer | Tax withheld | 3,850 | $1.9K |
| Jul 30, 2026 | Duarte Ira EVP, Chief Financial Officer | Option exercise | 13,535 | — |
| Jul 19, 2026 | Duarte Ira EVP, Chief Financial Officer | Option exercise | 3,874 | — |
| Jul 19, 2026 | Collard Craig A Chief Executive Officer | Option exercise | 13,797 | — |
| Jul 19, 2026 | Duarte Ira EVP, Chief Financial Officer | Tax withheld | 1,101 | $517 |
| Jul 19, 2026 | Forbes William P EVP, Chief Development Officer | Option exercise | 3,874 | — |
| Jul 19, 2026 | Forbes William P EVP, Chief Development Officer | Tax withheld | 1,101 | $517 |
| Jun 16, 2026 | Duarte Ira EVP, Chief Financial Officer | Tax withheld | 3,555 | $1.4K |
| Jun 16, 2026 | Duarte Ira EVP, Chief Financial Officer | Option exercise | 12,500 | — |
| Jun 6, 2026 | Forbes William P EVP, Chief Development Officer | Option exercise | 12,500 | — |
| May 6, 2026 | Hensley Mark Earl Chief Operating Officer | Option exercise | 125,000 | — |
| Apr 30, 2026 | Collard Craig A Chief Executive Officer | Option exercise | 34,789 | — |
| Apr 30, 2026 | Collard Craig A Chief Executive Officer | Option exercise | 50,021 | — |
| Apr 30, 2026 | Duarte Ira EVP, Chief Financial Officer | Option exercise | 11,694 | — |
| Apr 30, 2026 | Duarte Ira EVP, Chief Financial Officer | Option exercise | 13,535 | — |
| Apr 30, 2026 | Forbes William P EVP, Chief Development Officer | Option exercise | 11,694 | — |
| Apr 30, 2026 | Forbes William P EVP, Chief Development Officer | Option exercise | 11,770 | — |
| Apr 30, 2026 | Hensley Mark Earl Chief Operating Officer | Option exercise | 11,770 | — |
| Apr 19, 2026 | Duarte Ira EVP, Chief Financial Officer | Option exercise | 3,874 | — |
| Apr 19, 2026 | Collard Craig A Chief Executive Officer | Option exercise | 13,797 | — |
| Apr 19, 2026 | Forbes William P EVP, Chief Development Officer | Option exercise | 3,874 | — |
| Apr 3, 2026 | Collard Craig A Chief Executive Officer | Option exercise | 62,500 | — |
| Jan 31, 2026 | Duarte Ira EVP, Chief Financial Officer | Option exercise | 11,695 | — |
| Jan 31, 2026 | Collard Craig A Chief Executive Officer | Option exercise | 34,789 | — |
| Jan 31, 2026 | Forbes William P EVP, Chief Development Officer | Option exercise | 11,695 | — |
| Jan 30, 2026 | Johnson Craig A Director | Award | 53,960 | $0 |
| Jan 30, 2026 | Kaseta Michael Director | Award | 53,960 | $0 |
| Jan 30, 2026 | Morgan Adam Director | Award | 53,960 | $0 |
| Jan 30, 2026 | Christian Waage Director | Award | 53,960 | $0 |
| Jan 30, 2026 | Dissanaike Sharmila Director | Award | 53,960 | $0 |
| Jan 30, 2026 | Cusack Thomas Director | Award | 53,960 | $0 |
| Jan 19, 2026 | Duarte Ira EVP, Chief Financial Officer | Option exercise | 3,875 | — |
| Jan 19, 2026 | Forbes William P EVP, Chief Development Officer | Option exercise | 3,875 | — |
| Jan 19, 2026 | Collard Craig A Chief Executive Officer | Option exercise | 13,797 | — |
| Nov 8, 2025 | Cusack Thomas Director | Award | 37,879 | — |
| Oct 31, 2025 | Collard Craig A Chief Executive Officer | Option exercise | 34,789 | — |
| Oct 31, 2025 | Duarte Ira EVP, Chief Financial Officer | Option exercise | 11,694 | — |
| Oct 31, 2025 | Forbes William P EVP, Chief Development Officer | Option exercise | 11,694 | — |
| Oct 19, 2025 | Forbes William P EVP, Chief Development Officer | Option exercise | 3,874 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for HERON THERAPEUTICS, INC. /DE/
Free account. Everything above stays public.
Write why you follow HERON THERAPEUTICS, INC. /DE/ and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading